{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:43:18Z","timestamp":1759826598166},"reference-count":14,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2006,8,22]],"date-time":"2006-08-22T00:00:00Z","timestamp":1156204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>5\u2010aminosalicylic acid (mesalazine) is considered first\u2010line therapy for active mild\u2013moderate, left\u2010sided or extensive ulcerative colitis. With modern delayed\u2010release formulations, conventional doses are very well tolerated, and there is accumulating evidence that increasing the dose, to &gt;4\u2003g\/day, leads to higher response rates and earlier symptom relief in patients with ulcerative colitis.<\/jats:p><jats:p>There is evidence that combining oral and rectal (enema) formulations of 5\u2010aminosalicylic acid leads to faster and higher remission rates. Despite the fact that clinical trials in ulcerative colitis have often used different endpoints, making it difficult to make objective comparisons, the evidence now strongly suggests that it is appropriate to start patients with mild or moderately active ulcerative colitis on doses of 5\u2010aminosalicylic acid of at least 4\u2003g\/day.<\/jats:p><jats:p>For those with extensive disease, adding rectal 5\u2010aminosalicylic acid improves remission rates; the same seems likely to be true for limited disease, but robust evidence is lacking. Rectal 5\u2010aminosalicylic acid may in fact be sufficient on its own for patients with active proctitis. Patients with mild\u2013moderate ulcerative colitis who do not improve within 2\u2003weeks of high\u2010dose 5\u2010aminosalicylic acid should have treatment augmented by oral steroids.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2006.03070.x","type":"journal-article","created":{"date-parts":[[2006,8,22]],"date-time":"2006-08-22T08:19:11Z","timestamp":1156234751000},"page":"10-16","source":"Crossref","is-referenced-by-count":12,"title":["Review article: induction therapy for patients with active ulcerative colitis"],"prefix":"10.1111","volume":"24","author":[{"given":"S. P. L.","family":"TRAVIS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,8,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.043372"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603"},{"key":"e_1_2_6_4_2","first-page":"1188","article-title":"Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group","volume":"88","author":"Hanauer S","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_5_2","first-page":"CD000543","article-title":"Oral 5\u2010aminosalicylic acid for induction of remission in ulcerative colitis","volume":"3","author":"Sutherland L","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02018.x"},{"key":"e_1_2_6_7_2","first-page":"319","volume-title":"Inflammatory Bowel Diseases","author":"Irvine EJ","year":"2003"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-005-0079-9"},{"key":"e_1_2_6_9_2","first-page":"A 148","article-title":"Efficacy and safety of Asacol 4.8\u2003g\/day (800\u2003mg tablet) compared with 2.4\u2003g\/day (400\u2003mg tablet) in treating moderately active ulcerative colitis","volume":"20","author":"Hanauer SB","year":"2006","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00248.x"},{"key":"e_1_2_6_11_2","first-page":"A82","article-title":"SPD476, a novel once\u2010daily, high dose mesalazine formulation is well tolerated and effective for the induction of remission of mild\u2010 to moderate ulcerative colitis: a Phase III study [abstract]","volume":"54","author":"Lichtenstein G","year":"2005","journal-title":"Gut"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.060103"},{"key":"e_1_2_6_13_2","first-page":"1867","article-title":"A double\u2010blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis","volume":"92","author":"Safdi M","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_14_2","article-title":"Different definitions of remission for ulcerative colitis result in large variations of clinical outcome scores [DDW abstract]","author":"Katz S","year":"2006","journal-title":"Gastroenterology"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5375.89"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2006.03070.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2006.03070.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T09:11:46Z","timestamp":1694682706000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2006.03070.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,22]]},"references-count":14,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["10.1111\/j.1365-2036.2006.03070.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2006.03070.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,22]]}}}